Double-blind Methylphenidate Trials: Practical, Useful, and Highly Endorsed by Families
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate a 3-week, randomized, double-blind, methylphenidate placebo-controlled trial (MPT) in routine practice for children with attention-deficit disorder. PATIENTS AND METHODS: School-aged children with attention-deficit/hyperactivity disorder (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria) who enrolled an "N of 1" trial at a pediatric tertiary care center were eligible. Families (n = 50) with a child eligible for the MPT were given 3 bottles of identical capsules. The capsules contained, in random order: placebo of the prescribed dose of methylphenidate (Ritalin) hydrochloride (0.3 mg/kg or 0.6 mg/kg). Families gave the child 1 capsule at 8 AM and 1 capsule at noon. The family, teacher, and physician were blinded for the order of medication. Conners questionnaires (Conners Parent Questionnaire and Conners Teacher Questionnaire) and written comments were completed by parents and teachers at baseline and at the end of each week. Once MPT results were known and following discussion with the physician, families decided whether to continue methylphenidate therapy. Families were interviewed by telephone 14 to 21 months after the MPT. RESULTS: Forty-three (86%) of the 50 eligible children (mean age, 129 months) were contacted. No family found the MPT difficult, but 6 trials were incomplete, usually because of side effects. All families used the MPT to decide if methylphenidate was the correct treatment choice for their child and 68% (34 of 50 families) used the results exclusively. The remaining 16 families believed the MPT was helpful. Overall, 31 (72%) of the 43 children had a good response to methylphenidate treatment--20 (47%) continued to use it for longer than 12 months and 8 (26%) for 2 to 12 months; 3 responders chose not to use it after the MPT. Nine of the 43 families chose not to use methylphenidate treatment; however, all indicated that participating in the MPT helped them to make that decision. In follow-up interviews, the same proportion of methylphenidate users and nonusers reported improvement in many areas of function including significantly less time spent doing homework. Users reported reduced aggression (P<.001) and fewer discipline problems (P<.01) compared with nonusers. CONCLUSIONS: An "N of 1" MPT was easily performed and permitted families to decide whether to use methylphenidate for long-term treatment of attention-deficit disorder or attention-deficit/hyperactivity disorder. Regardless of methylphenidate use or lack of use, the condition of all of these children was improved at follow-up.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Placebo-Controlled Evaluation of Ritalin Side Effects
Ahmann, P. A., Waltonen, S. J., Theye, F. W., Olson, K. A., & Van Erem, A. J. (1993) · Pediatrics · doi:10.1542/peds.91.6.1101 · Cited by 178 · cited 4×
“However, those treated with methylphenidate have fewer difficulties than their untreated peers with ADD.9,10 Double-blind, placebo-controlled protocols for the use of methylphenidate have been reported previously.11-19 These studies, in which groups of children with ADD were randomized to 1 of 2 study treatment arms,…”
BackgroundInfluentialYoung Adult Outcome of Hyperactive Children Who Received Long-term Stimulant Treatment
HECHTMAN, L., WEISS, G., & PERLMAN, T. (1984) · Journal of the American Academy of Child Psychiatry · doi:10.1016/s0002-7138(09)60501-x · Cited by 178 · cited 1×
“Double-blind, placebo-controlled protocols for the use of methylphenidate have been reported previously.(11-19) These studies, in which groups of children with ADD were randomized to 1 of 2 study treatment arms, were designed to compare the efficacy of placebo and of methylphenidate.”
MethodMethylphenidate Dosing: Twice Daily Versus Three Times Daily
Stein, M. A., Blondis, T. A., Schnitzler, E. R., O'Brien, T., Fishkin, J., Blackwell, B., Szumowski, E., & Roizen, N. J. (1996) · Pediatrics · doi:10.1542/peds.98.4.748 · Cited by 151 · cited 1×
“Double-blind, placebo-controlled protocols for the use of methylphenidate have been reported previously.(11-19) These studies, in which groups of children with ADD were randomized to 1 of 2 study treatment arms, were designed to compare the efficacy of placebo and of methylphenidate.”
MethodDUPAUL, G. J., & RAPPORT, M. D. (1993) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199301000-00027 · Cited by 87 · cited 1×
“Double-blind, placebo-controlled protocols for the use of methylphenidate have been reported previously.(11-19) These studies, in which groups of children with ADD were randomized to 1 of 2 study treatment arms, were designed to compare the efficacy of placebo and of methylphenidate.”
Method
Cited by
The n-of-1 clinical trial: the ultimate strategy for individualizing medicine?
Lillie, E. O., Patay, B., Diamant, J., Issell, B., Topol, E. J., & Schork, N. J. (2011) · Personalized Medicine · doi:10.2217/pme.11.7 · Cited by 706
Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., Sutton, V. K., Gonzales, J., Malcolm, S. K., Schuh, K. J., et al. (2004) · Pediatrics · doi:10.1542/peds.114.1.e1 · Cited by 464
Locher, C., Koechlin, H., Zion, S. R., Werner, C., Pine, D. S., Kirsch, I., Kessler, R. C., & Kossowsky, J. (2017) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.2432 · Cited by 360
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)
Storebø, O. J., Ramstad, E., Krogh, H. B., Nilausen, T. D., Skoog, M., Holmskov, M., Rosendal, S., Groth, C., Magnusson, F. L., Moreira-Maia, C. R., et al. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009885.pub2 · Cited by 347
Aryl Transfer Strategies Mediated by Photoinduced Electron Transfer
Allen, A. R., Noten, E. A., & Stephenson, C. R. J. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00388 · Cited by 270
Metadata
- Authors
- Kent, M. A., Camfield, C. S., & Camfield, P. R.
- Venue
- Archives of Pediatrics & Adolescent Medicine
- Publisher
- American Medical Association (AMA)
- Published
- 1999-12-01
- Volume
- 153
- Issue
- 12
- Pages
- 1292
- ISSN
- 1072-4710 (ISSN-L)
- OpenAlex
- W2127122500
- Cited by
- 50
- References
- 4
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.